24 Stock Top Picks and 3 ETF (Jan 11-17)
This week there were 24 Top Picks and 3 ETF in a wide range of industries: ETF, Financials, Technology, Healtcare, Consumer, Basic Materials, Industrials, Energy, Telecommunications and Utilities.
Here are this week’s Top Picks as selected by: David Cockfield, Fabrice Taylor, James Hodgins, Brooke Thackray, Michael Sprung, Ryan Bushell, Jaime Carrasco, Robert McWhirte, Michael Simpson and David Driscoll.
Healthcare at the top, and then pharma and food. When we're seeing an early-cycle move, low vol tends to underperform. At this time, you want more cyclicals and growth. But great if you want low beta.
It is low Beta and skewed toward the more conservative sectors. It follows sector allocations and uses a checks and balances system for individual stocks.
20% off all time share price high.Market rally will lift shares to new records. Small cap indexes presenting opportunity.Better diversity in companies that make up index.
(A Top Pick Aug 09/22, Up 5%) Pleased that the First Horizon deal collapsed. TD pays a great return on invested capital, about 16%. Great staying power in Canada. The US is investigating it for their money-laundering compliance, but it's not a mortal threat and they'll likely be fined. Likes their big retail platform in…
Current share price very cheap.Earnings reasonable.Attractive given valuation at this time.New CEO has been under pressure to prove results to investors.~5% dividend relatively safe.Would buy a small amount at this price.
Stockchase Research Editor: Michael O'Reilly As quarterly cash reserves grow while debt is retired and shares bought back, we reiterate MFC as a TOP PICK. It pays a good dividend that has grown annually by 10% a year over the past decade. It trades at 7x earnings, 1.2x book and supports a robust 25% ROE. …
This is Fairfax's India subsidiary. It's cheaper to buy the parent company than FIH. Also buying a country-specific ETF is fine.
He has been investing in this for almost three years now. They received Health Canada approval for a new brain stimulation medical device last fall. They are awaiting FDA approval in the US. It magnifies the result of physio-therapy for the brain and the technology is safe. It is a billion dollar business if it…
Market's not liking the negative growth compared to the pandemic. China has impacted it, not as many IPOs. The market just needs to look beyond all this. High quality, grows by acquisition. Great CEO. In all the right places. Good time to take a look for long-term returns. A company like this is a 5-10…
They own a series of food distribution businesses. It appears they are not making any money from them. It appears to be a scale problem.
They saw two price target hikes today. TJX does well only when other retailers are struggling (a sign of a weakening economy). Once a consumer gets hooked on TJX, they don't go back.
(A Top Pick Jan 24/23, Down 10%) Cyclical business that hasn't performed well.Seasonality affecting share price (May-October).Expecting better performance of shares.Sign that economy is soft.
He has added more with the pullback. It has exposure to other fertilizers besides potash. Headwinds from the springtime are lessening and fertilizer demand is good for the long term.
To manage risk, he sets up his portfolios starting with the biggest, which is FNV. More diversified than OR. He also owns OSK proper.
He once owned it. The chart shows declining peaks since 2021, but int he past year shows a higher high and higher low. So, there's some potential. If it challenges its last peak of $3.50, it's a good sign. Are definitely some positives in this stock, so hold on and see if it breaks out.
target in Euros 400,000 employees globally handle call centres. Shares have fallen a lot in the past year partially due to labour practices in Colombia (being sorted out now). TEP holds a massive trove of data. They just signed a deal with Microsoft (cloud and AI), so that a machine on the other end will…
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. The quarter was a big miss; EPS $1.21 down from $1.61 the prior year and estimates of $1.54. Revenue $189.8M was higher than the prior year $188.6M but missed estimates of $203.4M. For 2023, guidance was $5.28 to $5.64 per share (est $5.44), Revenue guidance $878M to…
They're in northeast BC where Tourmaline is consolidating land and assets, near LXE. So, LXE will become topical. LXE has reached an inflection point after acquiring a lot of land and pushed the Montney play to the northeast. Now, they need a lot of capital to move to full development. They're talking to potential buyers,…
He lost faith in management and sold. It had cost over-runs and sold off some gas assets but not for great profits. Still more asset sales are needed to pay down debt. The plan to split the company into two parts raises question marks. Enbridge is better managed so he prefers that as well as…
Stockchase Research Editor: Michael O'Reilly We again reiterate VET as a TOP PICK. The company has aggressively reduced debt all the way down to one year's cash flow and its energy portfolio is well diversified. It trades at 6x earnings, under book value and supports a 36% ROE. We recommend trailing up the stop (from…
He targets $47 or 13% lower. It yields 3.7% that they can cover. But the market isn't excited, plus this is sensitive to interest rates. It's only slightly better than BCE. Maybe it's interesting at $41.
Great Canadian company.Hard assets, but current share price too high.Waiting for share price to fall ~$10.Very safe dividend.
Core income stock. Time to build a position. Reaffirmed annual dividend growth of 4-6% until 2028. Investment-grade balance sheet. More than 50% of revenues are from US. Reasonable payout ratio. Yield is 4.3%, and grows every year. (Analysts’ price target is $57.95)